Research programme: pancreatitis therapeutics - Johns Hopkins School of Medicine/NuMedii
Latest Information Update: 28 Dec 2022
Price :
$50 *
At a glance
- Originator Johns Hopkins University School of Medicine; NuMedii
- Class Anti-inflammatories
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Pancreatitis
Most Recent Events
- 28 Dec 2022 No recent reports of development identified for research development in Pancreatitis in USA
- 01 Nov 2018 NuMedii enters into a research collaboration with Johns Hopkins School of Medicine to discover new targets and therapeutics for Pancreatitis
- 01 Nov 2018 Early research in Pancreatitis in USA (unspecified route)